Fiche centre
The first Affiliated Hospital, Zhejiang University School of Medicine ( Site 3115)
Hangzhou — China
Essais liés2clinical trials
VilleHangzhoulocalisation
PaysChinalocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT06170788
Essais cliniques associés
2| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Calderasib | Parkinson | Phase 3 | NCT06345729 | A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | RECRUITING |
| Sacituzumab Tirumotecan | Parkinson | Phase 3 | NCT06170788 | TroFuse-007 — Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | RECRUITING |